Gary Calandra

8.4k total citations · 3 hit papers
104 papers, 6.2k citations indexed

About

Gary Calandra is a scholar working on Hematology, Public Health, Environmental and Occupational Health and Immunology. According to data from OpenAlex, Gary Calandra has authored 104 papers receiving a total of 6.2k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Hematology, 28 papers in Public Health, Environmental and Occupational Health and 24 papers in Immunology. Recurrent topics in Gary Calandra's work include Hematopoietic Stem Cell Transplantation (32 papers), Streptococcal Infections and Treatments (20 papers) and Acute Myeloid Leukemia Research (14 papers). Gary Calandra is often cited by papers focused on Hematopoietic Stem Cell Transplantation (32 papers), Streptococcal Infections and Treatments (20 papers) and Acute Myeloid Leukemia Research (14 papers). Gary Calandra collaborates with scholars based in United States, Italy and Australia. Gary Calandra's co-authors include Gary Bridger, John F. DiPersio, David C. Dale, Hal E. Broxmeyer, W. Conrad Liles, Giao Hangoc, Karin Badel, Richard T. Maziarz, Patrick J. Stiff and Ivana N. Micallef and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and The Journal of Experimental Medicine.

In The Last Decade

Gary Calandra

103 papers receiving 5.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist

2005 848 citations Hal E. Broxmeyer, Christie M. Orschell et al. The Journal of Experimental Medicine profile →
Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonist

2003 561 citations W. Conrad Liles, Hal E. Broxmeyer et al. Blood profile →
Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma

2009 512 citations John F. DiPersio, Ivana N. Micallef et al. Journal of Clinical Oncology profile →

Peers

Gary Calandra

HEMAT

IMMUN

ONCOL

EPIDE

Seymour Katz United States

Gilles Kaplanski France

Mark Ballow United States

Gregory R. Harriman United States

François Spertini Switzerland

Steven H. Sacks United Kingdom

Paul S. Russell United States

Cynthia Guzzo United States

Marc Lémann France

Jeffrey A. Gelfand United States

Seymour Katz United States

Gary Calandra

533 ×0.2

HEMAT

4.1k ×2.2

IMMUN

935 ×0.5

ONCOL

2.5k ×2.4

EPIDE

1.3k ×1.4

Citations per year, relative to Gary Calandra Gary Calandra (= 1×) peers Seymour Katz

Countries citing papers authored by Gary Calandra

Since Specialization

Citations

This map shows the geographic impact of Gary Calandra's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary Calandra with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary Calandra more than expected).

Fields of papers citing papers by Gary Calandra

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gary Calandra. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary Calandra. The network helps show where Gary Calandra may publish in the future.

Co-authorship network of co-authors of Gary Calandra

This figure shows the co-authorship network connecting the top 25 collaborators of Gary Calandra. A scholar is included among the top collaborators of Gary Calandra based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gary Calandra. Gary Calandra is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Biggio, Francesca, Maria Cristina Mostallino, Giuseppe Talani, et al.. (2019). Social enrichment reverses the isolation-induced deficits of neuronal plasticity in the hippocampus of male rats. Neuropharmacology. 151. 45–54. 50 indexed citations

Pantin, Jeremy, Enkhtsetseg Purev, Xin Tian, et al.. (2016). Effect of high-dose plerixafor on CD34 ⁺ cell mobilization in healthy stem cell donors: results of a randomized crossover trial. Haematologica. 102(3). 600–609. 44 indexed citations

Kaufman, Jonathan L., Christopher R. Flowers, Gary Calandra, et al.. (2012). A prospective clinical trial evaluating the safety and efficacy of the combination of rituximab and plerixafor as a mobilization regimen for patients with lymphoma. Transfusion. 53(1). 76–84. 2 indexed citations

DiPersio, John F., Ivana N. Micallef, Patrick J. Stiff, et al.. (2009). Phase III Prospective Randomized Double-Blind Placebo-Controlled Trial of Plerixafor Plus Granulocyte Colony-Stimulating Factor Compared With Placebo Plus Granulocyte Colony-Stimulating Factor for Autologous Stem-Cell Mobilization and Transplantation for Patients With Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 27(28). 4767–4773. 512 indexed citations breakdown →

Stiff, Patrick J., Ivana N. Micallef, Philip L. McCarthy, et al.. (2009). Treatment with Plerixafor in non-Hodgkin's Lymphoma and Multiple Myeloma Patients to Increase the Number of Peripheral Blood Stem Cells When Given a Mobilizing Regimen of G-CSF: Implications for the Heavily Pretreated Patient. Biology of Blood and Marrow Transplantation. 15(2). 249–256. 86 indexed citations

Fowler, Cedar, Keith Hansen, Lisa Hansen, et al.. (2009). Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplantation. 43(12). 909–917. 57 indexed citations

Devine, Steven M., Ravi Vij, Michael P. Rettig, et al.. (2008). Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 112(4). 990–998. 234 indexed citations

Stiff, Patrick J., Philip L. McCarthy, Margarida Magalhaes‐Silverman, et al.. (2005). AMD3100 plus G-CSF rapidly mobilizes hematopoietic progenitor cells in patients with non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM), including those traditionally considered “poor mobilizers”. Biology of Blood and Marrow Transplantation. 11(2). 92–92. 1 indexed citations

Broxmeyer, Hal E., Christie M. Orschell, D. Wade Clapp, et al.. (2005). Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. The Journal of Experimental Medicine. 201(8). 1307–1318. 848 indexed citations breakdown →

10.

Lack, Nathan A., David C. Dale, Gary Calandra, et al.. (2005). A pharmacokinetic-pharmacodynamic model for the mobilization of CD34 hematopoietic progenitor cells by AMD3100. Clinical Pharmacology & Therapeutics. 77(5). 427–436. 61 indexed citations

11.

Vermeire, Kurt, Sigrid Hatse, Katrien Princen, et al.. (2004). Virus resistance to the CXCR4 inhibitor AMD070 develops slowly and does not induce a co-receptor switch. Antiviral Research. 62. 2 indexed citations

12.

Hübel, Kai, W. Conrad Liles, Hal E. Broxmeyer, et al.. (2004). Leukocytosis and Mobilization of CD34+ Hematopoietic Progenitor Cells by AMD3100, a CXCR4 Antagonist. PubMed. 1(3). 165–172. 77 indexed citations

13.

Pirovano, Silvia, et al.. (2003). Low Thymic Output and Reduced Heterogeneity of Alpha/Beta, but not Gamma/Delta, T Lymphocytes in Infants with Ataxia-Telangiectasia. Neuropediatrics. 34(3). 165–167. 10 indexed citations

14.

Calandra, Gary, L.J. Lukacs, Leslie Jonas, et al.. (1993). Anti-PRP antibody levels after a primary series of PRP-OMPC and persistence of antibody titres following primary and booster doses. Vaccine. 11. S58–S62. 14 indexed citations

15.

Werzberger, Alan, Barbara Mensch, Barbara J. Kuter, et al.. (1992). A Controlled Trial of a Formalin-Inactivated Hepatitis A Vaccine in Healthy Children. New England Journal of Medicine. 327(7). 453–457. 389 indexed citations

16.

Ahonkhai, Vincent I., L.J. Lukacs, Leslie Jonas, & Gary Calandra. (1991). Clinical experience with PedvaxHIB, a conjugate vaccine of Haemophilus influenzae type b polysaccharide—Neisseria meningitidis outer membrane protein. Vaccine. 9. S38–S41. 15 indexed citations

17.

West, David J., Gary Calandra, & Ronald W. Ellis. (1990). Vaccination of Infants and Children Against Hepatitis B. Pediatric Clinics of North America. 37(3). 585–601. 35 indexed citations

18.

Calandra, Gary, et al.. (1988). The Efficacy Results and Safety Profile of Imipenem/Cilastatin from the Clinical Research Trials. The Journal of Clinical Pharmacology. 28(2). 120–127. 31 indexed citations

19.

Calandra, Gary, et al.. (1987). Problems and Benefits of an Antibiotic Compassionate Therapy Program. Clinical Infectious Diseases. 9(6). 1095–1101. 5 indexed citations

20.

Shama, Steven K. & Gary Calandra. (1982). Atypical erysipelas caused by group G streptococci in a patient with cured Hodgkin's disease.. PubMed. 118(11). 934–6. 17 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact